The function and performance of aqueous aerosol devices for inhalation therapy

Journal of Pharmacy and Pharmacology

Volumn 68, Issue 5, 2016, Pages 556-578

  Carvalho, Thiago C ^a   McConville, Jason T ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

aerosol solution; aerosol suspension; lung targeting; nebulizer function; protein therapeutics

Indexed keywords

AMPHOTERICIN B; BUDESONIDE; AEROSOL; DRUG;

AQUEOUS AEROSOL DEVICE; AQUEOUS SOLUTION; CAPILLARY AEROSOL GENERATION; CAPILLARY AEROSOL GENERATOR; CHEMICAL PHENOMENA; COLLIDING JET MECHANISM; CONCENTRATION (PARAMETERS); DROPLET; DRUG DELIVERY DEVICE; DRUG FORMULATION; ELECTROHYDRODYNAMIC MECHANISM; EQUIPMENT DESIGN; EXTRUDED JET MECHANISM; GENERAL MEDICAL DEVICE; INHALATIONAL DRUG ADMINISTRATION; ION CONCENTRATION; JET NEBULIZER; LIPID NANOEMULSION; LIPOSOMAL FORMULATION; NANOEMULSION; NEBULIZATION; NEBULIZER; PARTICLE DEPOSITION; PARTICLE SIZE; PHYSICAL CHEMISTRY; PHYSICAL PHENOMENA; REVIEW; SURFACE ACOUSTIC WAVE MICROFLUIDIC ATOMIZATION; SURFACE TENSION; SUSPENSION; TEMPERATURE DEPENDENCE; ULTRASONIC NEBULIZER; VIBRATING MESH NEBULIZER; VISCOSITY; AEROSOL; ANIMAL; CHEMISTRY; DEVICES; DRUG DELIVERY SYSTEM; HUMAN; MASS COMMUNICATION; SURFACE PROPERTY;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; DIFFUSION OF INNOVATION; DRUG COMPOUNDING; DRUG DELIVERY SYSTEMS; EQUIPMENT DESIGN; HUMANS; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; PHARMACEUTICAL PREPARATIONS; SURFACE PROPERTIES;

EID: 84963781875     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12541     Document Type: Review

References (232)

1. Boe J, et al,. European Respiratory Society Guidelines on the use of nebulizers. Eur Respir J 2001; 18: 228-242.
2. Leung K, et al,. Comparison of breath-enhanced to breath-actuated nebulizers for rate, consistency, and efficiency. Chest 2004; 126: 1619-1627.
3. Denyer J, Dyche T,. The adaptive aerosol delivery (AAD) technology: past, present, and future. J Aerosol Med Pulm Drug Deliv 2010; 23: S1-S10.
4. Hardaker LEA, Hatley RHM,. In vitro characterization of the I-neb adaptive aerosol delivery (AAD) system. J Aerosol Med Pulm Drug Deliv 2010; 23: S11-S20.
5. Geller DE,. The science of aerosol delivery in cystic fibrosis. Pediatr Pulmonol 2008; 43: S5-S17.
6. Mudaliar S,. Inhaled insulin using AERx (R) insulin diabetes management system (AERx (R) iDMS). Expert Opin Investig Drugs 2007; 16: 1673-1681.
7. Owens DR, et al,. Alternative routes of insulin delivery. Diabet Med 2003; 20: 886-898.
8. Julius SM, et al,. Accuracy of three electronic monitors for metered-dose inhalers. Chest 2002; 121: 871-876.
9. Carvalho TC, et al,. Influence of particle size on regional lung deposition-What evidence is there? Int J Pharm 2011; 406: 1-10.
10. Ocallaghan C, et al,. Inaccurate calculation of drug output from nebulizers. Eur J Pediatr 1989; 148: 473-474.
11. Thi THH, et al,. Characterization and in vitro evaluation of the formoterol/cyclodextrin complex for pulmonary administration by nebulization. Eur J Pharm Biopharm 2009; 72: 214-218.
12. Elhissi AMA, Taylor KMG,. Delivery of liposomes generated from proliposomes using air-jet, ultrasonic, and vibrating-mesh nebulisers. J Drug Deliv Sci Technol 2005; 15: 261-265.
13. Gurses BK, Smaldone GC,. Effect of tubing deposition, breathing pattern, and temperature on aerosol mass distribution measured by cascade impactor. J Aerosol Med-Deposit Clearance Effects Lung 2003; 16: 387-394.
14. McCallion ONM, et al,. Jet nebulisers for pulmonary drug delivery. Int J Pharm 1996; 130: 1-11.
15. Mercer TT,. Production of therapeutic aerosols-principles and techniques. Chest 1981; 80: 813-818.
16. Smith EC, et al,. Comparison of 23 nebulizer compressor combinations for domiciliary use. Eur Respir J 1995; 8: 1214-1221.
17. Bendstrup KE, et al,. Characterization of heparin aerosols generated in jet and ultrasonic nebulizers. J Aerosol Med-Deposit Clearance Effects Lung 1999; 12: 17-25.
18. Coates AL, et al,. The choice of jet nebulizer, nebulizing flow, and addition of albuterol affects the output of tobramycin aerosols. Chest 1997; 111: 1206-1212.
19. Arzhavitina A, Steckel H,. Surface active drugs significantly alter the drug output rate from medical nebulizers. Int J Pharm 2010; 384: 128-136.
20. Pilcer G, Amighi K,. Formulation strategy and use of excipients in pulmonary drug delivery. Int J Pharm 2010; 392: 1-19.
21. Sood BG, et al,. Jet nebulization of prostaglandin E-1 during neonatal mechanical ventilation: stability, emitted dose and aerosol particle size. Pharmacol Res 2007; 56: 531-541.
22. Steckel H, Eskandar F,. Factors affecting aerosol performance during nebulization with jet and ultrasonic nebulizers. Eur J Pharm Sci 2003; 19: 443-455.
23. McCallion ONM, et al,. Nebulization of fluids of different physicochemical properties with air-jet and ultrasonic nebulizers. Pharm Res 1995; 12: 1682-1688.
24. McCallion ONM, et al,. The influence of surface tension on aerosols produced by medical nebulisers. Int J Pharm 1996; 129: 123-136.
25. McCallion ONM, Patel MJ,. Viscosity effects on nebulisation of aqueous solutions. Int J Pharm 1996; 130: 245-249.
26. Broniarz-Press L, et al,. The effect of shear and extensional viscosity on atomization in medical inhaler. Int J Pharm 2014; 468: 199-206.
27. Diot P, et al,. RhDNase I aerosol deposition and related factors in cystic fibrosis. Am J Respir Crit Care Med 1997; 156: 1662-1668.
28. Johnson JC, et al,. Aerosol delivery of recombinant human DNase I. In vitro comparison of a vibrating-mesh nebulizer with a jet nebulizer. Respiratory Care 2008; 53: 1703-1708.
29. Fiel SB, et al,. Comparison of three jet nebulizer aerosol delivery systems used to administer recombinant human DNase-I to patients with cystic fibrosis. Chest 1995; 108: 153-156.
30. Geller DE, et al,. Effect of smaller droplet size of dornase alfa on lung function in mild cystic fibrosis. Pediatr Pulmonol 1998; 25: 83-87.
31. Germershaus O, et al,. Insulin-like growth factor-I aerosol formulations for pulmonary delivery. Eur J Pharm Biopharm 2013; 85: 61-68.
32. Niven RW, et al,. Protein nebulization.2. Stabilization of G-CSF to air-jet nebulization and the role of protectants. Int J Pharm 1996; 127: 191-201.
33. Albasarah YY, et al,. Stabilizing protein formulations during air-jet nebulization. Int J Pharm 2010; 402: 140-145.
34. Chang LQ, Pikal MJ,. Mechanisms of protein stabilization in the solid state. J Pharm Sci 2009; 98: 2886-2908.
35. Steckel H, et al,. Effect of cryoprotectants on the stability and aerosol performance of nebulized aviscumine, a 57-kDa protein. Eur J Pharm Biopharm 2003; 56: 11-21.
36. Flament MP, et al,. Influence of formulation on jet nebulisation quality of alpha(1) protease inhibitor. Int J Pharm 1999; 178: 101-109.
37. Terzano C, et al,. Comparison of the efficacy of beclometasone dipropionate and fluticasone propionate suspensions for nebulization in adult patients with persistent asthma. Respir Med 2003; 97: S35-S40.
38. Britland S, et al,. Droplet aerodynamics, cellular uptake, and efficacy of a nebulizable corticosteroid nanosuspension are superior to a micronized dosage form. Biotechnol Prog 2012; 28: 1152-1159.
39. Barry PW, O'Callaghan C,. An in vitro analysis of the output of budesonide from different nebulizers. J Allergy Clin Immunol 1999; 104: 1168-1173.
40. Dahlstrom K, et al,. Systemic availability and lung deposition of budesonide via three different nebulizers in adults. Annals Allergy Asthma Immunol 2003; 90: 226-232.
41. Berg EB, Picard RJ,. In vitro delivery of budesonide from 30 jet nebulizer/compressor combinations using infant and child breathing patterns. Respiratory Care 2009; 54: 1671-1678.
42. Vaghi A, et al,. In vitro comparison of nebulised budesonide (Pulmicort Respuless (R)) and beclomethasone dipropionate (Clenil (R) per Aerosol). Pulm Pharmacol Ther 2005; 18: 151-153.
43. Najlah M, et al,. The effects of suspension particle size on the performance of air-jet, ultrasonic and vibrating-mesh nebulisers. Int J Pharm 2014; 461: 234-241.
44. Amani A, et al,. Evaluation of a nanoemulsion-based formulation for respiratory delivery of budesonide by nebulizers. Aaps Pharmscitech 2010; 11: 1147-1151.
45. Nasr M, et al,. Amphotericin B lipid nanoemulsion aerosols for targeting peripheral respiratory airways via nebulization. Int J Pharm 2012; 436: 611-616.
46. Moazeni E, et al,. Preparation and evaluation of inhalable itraconazole chitosan based polymeric micelles. DARU J Pharmaceut Sci 2012; 20: 85.
47. Gilani K, et al,. Development of respirable nanomicelle carriers for delivery of amphotericin B by jet nebulization. J Pharm Sci 2011; 100: 252-259.
48. Osman R, et al,. Enhanced properties of discrete pulmonary deoxyribonuclease I (DNaseI) loaded PLGA nanoparticles during encapsulation and activity determination. Int J Pharm 2011; 408: 257-265.
49. Tadros MI,. The influence of sodium hyaluronate, L-leucine and sodium taurocholate on the nebulization of aqueous betamethasone-17-valerate suspensions. Aaps Pharmscitech 2008; 9: 243-249.
50. Dailey LA, et al,. Nebulization of biodegradable nanoparticles: impact of nebulizer technology and nanoparticle characteristics on aerosol features. J Controlled Release 2003; 86: 131-144.
51. Gaspar MM, et al,. Inhaled liposomes-current strategies and future challenges. J Biomed Nanotechnol 2008; 4: 245-257.
52. Waldrep JC, et al,. High dose cyclosporin A and budesonide-liposome aerosols. Int J Pharm 1997; 152: 27-36.
53. Bridges PA, Taylor KMG,. An investigation of some of the factors influencing the jet nebulisation of liposomes. Int J Pharm 2000; 204: 69-79.
54. Desai TR, et al,. A facile method of delivery of liposomes by nebulization. J Controlled Release 2002; 84: 69-78.
55. Davies LA, et al,. Aerosol delivery of DNA/Liposomes to the lung for cystic fibrosis gene therapy. Human Gene Therapy Clin Develop 2014; 25: 97-107.
56. Elhissi AMA, et al,. Formulations generated from ethanol-based proliposomes for delivery via medical nebulizers. J Pharm Pharmacol 2006; 58: 887-894.
57. Elhissi AMA, et al,. Physical stability and aerosol properties of liposomes delivered using an air-jet nebulizer and a novel micropump device with large mesh apertures. Int J Pharm 2007; 334: 62-70.
58. Chimote G, Banerjee R,. In vitro evaluation of inhalable isoniazid-loaded surfactant liposomes as an adjunct therapy in pulmonary tuberculosis. J Biomed Mat Res Part B-Appl Biomat 2010; 94B: 1-10.
59. Chimote G, Banerjee R,. Evaluation of antitubercular drug-loaded surfactants as inhalable drug-delivery systems for pulmonary tuberculosis. J Biomed Mater Res, Part A 2009; 89A: 281-292.
60. Yeo LY, et al,. Ultrasonic nebulization platforms for pulmonary drug delivery. Expert Opin Drug Delivery 2010; 7: 663-679.
61. Ramisetty KA, et al,. Investigations into ultrasound induced atomization. Ultrason Sonochem 2013; 20: 254-264.
62. Beck-Broichsitter M, et al,. Impact of lyoprotectants for the stabilization of biodegradable nanoparticles on the performance of air-jet, ultrasonic, and vibrating-mesh nebulizers. Eur J Pharm Biopharm 2012; 82: 272-280.
63. Flament MP, et al,. Influence of the technological parameters of ultrasonic nebulisation on the nebulisation quality of alpha 1 protease inhibitor (alpha 1I). Int J Pharm 1999; 189: 197-204.
64. Khatri L, et al,. An assessment of jet and ultrasonic nebulisers for the delivery of lactate dehydrogenase solutions. Int J Pharm 2001; 227: 121-131.
65. Broniarz-Press L, et al,. The effect of shear and extensional viscosities on atomization of Newtonian and non-Newtonian fluids in ultrasonic inhaler. Int J Pharm 2015; 485: 41-49.
66. Nikander K, et al,. The conventional ultrasonic nebulizer proved inefficient in nebulizing a suspension. J Aerosol Med-Deposit Clearance Effects Lung 1999; 12: 47-53.
67. Lehofer B, et al,. Impact of atomization technique on the stability and transport efficiency of nebulized liposomes harboring different surface characteristics. Eur J Pharm Biopharm 2014; 88: 1076-1085.
68. Videira MA, et al,. Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles. J Drug Target 2002; 10: 607-613.
69. Pardeike J, et al,. Development of an Itraconazole-loaded nanostructured lipid carrier (NLC) formulation for pulmonary application. Int J Pharm 2011; 419: 329-338.
70. Newman S, Gee-Turner A,. The Omron MicroAir vibrating mesh technology nebuliser, a 21st century approach to inhalation therapy. J Applied Therap Res 2005; 5: 29-33.
71. Elhissi A, et al,. Air-jet and vibrating-mesh nebulization of niosomes generated using a particulate-based proniosome technology. Int J Pharm 2013; 444: 193-199.
72. Lass JS, et al,. New advances in aerosolised drug delivery: vibrating membrane nebuliser technology. Exp Opin Drug Deliv 2006; 3: 693-702.
73. Watts AB, et al,. Current therapies and technological advances in aqueous aerosol drug delivery. Drug Dev Ind Pharm 2008; 34: 913-922.
74. Hertel S, et al,. That's cool!-Nebulization of thermolabile proteins with a cooled vibrating mesh nebulizer. Eur J Pharm Biopharm 2014; 87: 357-365.
75. Coates AL, et al,. Higher Tobramycin concentration and vibrating mesh technology can shorten antibiotic treatment time in cystic fibrosis. Pediatr Pulmonol 2011; 46: 401-408.
76. Coates AL, et al,. Testing of nebulizers for delivering magnesium sulfate to pediatric asthma patients in the emergency department. Respiratory Care 2011; 56: 314-318.
77. Ghazanfari T, et al,. The influence of fluid physicochemical properties on vibrating-mesh nebulization. Int J Pharm 2007; 339: 103-111.
78. Zhang G, et al,. Performance of the vibrating membrane aerosol generation device: Aeroneb micropump nebulizer (TM). J Aeros Med-Deposit Clear Effects Lung 2007; 20: 408-416.
79. Chan JGY, et al,. Delivery of high solubility polyols by vibrating mesh nebulizer to enhance mucociliary clearance. J Aerosol Med Pulm Drug Deliv 2012; 25: 297-305.
80. Beck-Broichsitter M, et al,. On the correlation of output rate and aerodynamic characteristics in vibrating-mesh-based aqueous aerosol delivery. Int J Pharm 2014; 461: 34-37.
81. ®rapid: impact of formulation variables on aerodynamic characteristics. J Pharm Sci 2014; 103: 2585-2589.
82. Chan JGY, et al,. Mannitol delivery by vibrating mesh nebulisation for enhancing mucociliary clearance. J Pharm Sci 2011; 100: 2693-2702.
83. Najlah M, et al,. A study of the effects of sodium halides on the performance of air-jet and vibrating-mesh nebulizers. Int J Pharm 2013; 456: 520-527.
84. ® pharmaceutical nebulizer. Europ J Nanomed 2014; 6: 29-36.
85. Rottier BL, et al,. Changes in performance of the Pari eFlow (R) rapid and Pari LC Plus (TM) during 6 months use by CF patients. J Aerosol Med Pulm Drug Deliv 2009; 22: 263-269.
86. Pitance L, et al,. Delivery efficacy of a vibrating mesh nebulizer and a jet nebulizer under different configurations. J Aerosol Med Pulm Drug Deliv 2010; 23: 389-396.
87. Ari A, et al,. Influence of nebulizer type, position, and bias flow on aerosol drug delivery in simulated pediatric and adult lung models during mechanical ventilation. Respiratory Care 2010; 55: 845-851.
88. Skaria S, Smaldone GC,. Omron NE U22: Comparison between vibrating mesh and jet nebulizer. J Aerosol Med Pulm Drug Deliv 2010; 23: 173-180.
89. ® nebulizer. J Aerosol Med Pulm Drug Deliv 2011; 24: 157-163.
90. Lenney W, et al,. Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects. J Cyst Fibros 2011; 10: 9-14.
91. Harris K,. et al. In vitro effects of vibrating mesh nebulization and radiopharmaceuticals on interferon gamma. In: European Respiratory Society. 2007.
92. ® vibrating membrane nebulizers: aerosol characteristics and physicochemical stability. J Pharm Sci 2011; 100: 98-109.
93. Hertel S, et al,. Prediction of protein degradation during vibrating mesh nebulization via a high throughput screening method. Eur J Pharm Biopharm 2014; 87: 386-394.
94. McConville JT, et al,. Targeted high lung concentrations of itraconazole using nebulized dispersions in a murine model. Pharm Res 2006; 23: 901-911.
95. Tam JM, et al,. Amorphous cyclosporin nanodispersions for enhanced pulmonary deposition and dissolution. J Pharm Sci 2008; 97: 4915-4933.
96. Vaughn JM, et al,. Single dose and multiple dose studies of itraconazole nanoparticles. Eur J Pharm Biopharm 2006; 63: 95-102.
97. Beck-Broichsitter M, et al,. Following the concentration of polymeric nanoparticles during nebulization. Pharm Res 2013; 30: 16-24.
98. Beck-Broichsitter M, et al,. Boosting the aerodynamic properties of vibrating-mesh nebulized polymeric nanosuspensions. Int J Pharm 2014; 459: 23-29.
99. Watts AB, et al,. Preclinical evaluation of tacrolimus colloidal dispersion for inhalation. Eur J Pharm Biopharm 2011; 77: 207-215.
100. Beck-Broichsitter M, et al,. Pulmonary drug delivery with aerosolizable nanoparticles in an ex vivo lung model. Int J Pharm 2009; 367: 169-178.
101. Packhaeuser CB, et al,. Stabilization of aerosolizable nano-carriers by freeze-drying. Pharm Res 2009; 26: 129-138.
102. Li ZL, et al,. Characterization of nebulized liposomal amikacin (Arikace (TM)) as a function of droplet size. J Aerosol Med Pulm Drug Deliv 2008; 21: 245-253.
103. Elhissi AMA, et al,. Nebulization of ultradeformable liposomes: the influence of aerosolization mechanism and formulation excipients. Int J Pharm 2012; 436: 519-526.
104. Elhissi A, et al,. Vibrating-mesh nebulization of liposomes generated using an ethanol-based proliposome technology. J Liposome Res 2011; 21: 173-180.
105. Beck-Broichsitter M, et al,. Correlation of drug release with pulmonary drug absorption profiles for nebulizable liposomal formulations. Eur J Pharm Biopharm 2013; 84: 106-114.
106. Fuchs S, et al,. Towards an inhalative in vivo application of immunomodulating gelatin nanoparticles in horse-related preformulation studies. J Microencapsul 2012; 29: 615-625.
107. Nasr M, et al,. PAMAM dendrimers as aerosol drug nanocarriers for pulmonary delivery via nebulization. Int J Pharm 2014; 461: 242-250.
108. Carvalho TC, et al,. Development and characterization of phospholipid-stabilized submicron aqueous dispersions of coenzyme Q10 presenting continuous vibrating-mesh nebulization performance. J Liposome Res 2013; 23: 276-290.
109. Longest PW, Hindle M,. Evaluation of the respimat soft mist inhaler using a concurrent CFD and in vitro approach. J Aerosol Med Pulm Drug Deliv 2009; 22: 99-112.
110. Pitcairn G, et al,. Deposition of corticosteroid aerosol in the human lung by Respimat (R) Soft Mist (TM) Inhaler compared to deposition by metered dose inhaler or by Turbuhaler (R) dry powder inhaler. J Aeros Med-Deposit Clear Effects Lung 2005; 18: 264-272.
111. Zierenberg B,. Optimizing the in vitro performance of Respimat. J Aeros Med-Deposit Clear Effects Lung 1999; 12: S19-S24.
112. Hochrainer D, et al,. Comparison of the aerosol velocity and spray duration of Respimat (R) Soft Mist (TM) Inhaler and pressurized metered dose inhalers. J Aeros Med-Deposit Clearan Effects Lung 2005; 18: 273-282.
113. Dalby R, et al,. A review of the development of Respimat((R)) Soft Mist (TM) Inhaler. Int J Pharm 2004; 283: 1-9.
114. Dolovich MB, Dhand R,. Aerosol drug delivery: developments in device design and clinical use. Lancet 2011; 377: 1032-1045.
115. ™ Inhaler: a review of its use in chronic obstructive pulmonary disease. Drugs 2014; 74: 1801-1816.
116. Spallek MW, et al,. Optimizing nozzles for soft mist inhalers. In: Respiratory Drug Delivery VIII. Tucson, AZ, USA: Virginia Commonwealth University, Richmond, VA, USA, 2002.
117. Son YJ, McConville JT,. Advancements in dry powder delivery to the lung. Drug Dev Ind Pharm 2008; 34: 948-959.
118. Islam N, Gladki E,. Dry powder inhalers (DPIs)-a review of device reliability and innovation. Int J Pharm 2008; 360: 1-11.
119. Kesser KC, Geller DE,. New aerosol delivery devices for cystic fibrosis. Respiratory Care 2009; 54: 754-767.
120. Kunkel G, et al,. Respimat (R) (a new soft mist inhaler) delivering fenoterol plus ipratropium bromide provides equivalent bronchodilation at half the cumulative dose compared with a conventional metered dose inhaler in asthmatic patients. Respiration 2000; 67: 306-314.
121. Goldberg J, et al,. Improved delivery of fenoterol plus ipratropium bromide using Respimat (R) compared with a conventional metered dose inhaler. Eur Respir J 2001; 17: 225-232.
122. Hodder R, et al,. Low incidence of paradoxical bronchoconstriction in asthma and COPD patients during chronic use of Respimat (R) soft mist (TM) inhaler. Respir Med 2005; 99: 1087-1095.
123. Koehler D, et al,. Low incidence of paradoxical bronchoconstriction with bronchodilator drugs administered by Respimat (R) Soft Mist (TM) Inhaler: Results of phase II single-dose crossover studies. Respiration 2004; 71: 469-476.
124. von Berg A, et al,. Efficacy and safety of Ipratropium bromide plus fenoterol inhaled via Respimat (R) Soft Mist (TM) inhaler vs. A conventional metered dose inhaler plus Spacer in children with asthma. Pediatr Pulmonol 2004; 37: 264-272.
125. Vincken W, et al,. Long-term efficacy and safety of ipratropium bromide plus fenoterol via Respimat (R) Soft Mist (TM) inhaler (SMI) versus a pressurised metered-dose inhaler in asthma. Clin Drug Invest 2004; 24: 17-28.
126. Iacono P, et al,. Improved delivery of ipratropium bromide using Respimat (R) (a new soft mist inhaler) compared with a conventional metered dose inhaler: cumulative dose response study in patients with COPD. Respir Med 2000; 94: 490-495.
127. Kilfeather SA, et al,. Improved delivery of ipratropium bromide/fenoterol from Respimat (R) Soft Mist (TM) Inhaler in patients with COPD. Respir Med 2004; 98: 387-397.
128. Anderson P,. Use of Respimat Soft Mist inhaler in COPD patients. Int J Chron Obstruct Pulmon Dis 2006; 1: 251-259.
129. ZuWallack R, et al,. Efficacy and safety of ipratropium bromide/albuterol delivered via Respimat (R) inhaler versus MDI. Respir Med 2010; 104: 1179-1188.
130. Kerstjens HAM, et al,. Tiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial. J Allergy Clin Immunol 2011; 128: 308-314.
131. Singh S, et al,. Mortality associated with tiotropium mist inhaler in patients with chronic obstructive pulmonary disease: systematic review and meta-analysis of randomised controlled trials. Br Med J 2011; 342: d3215.
132. Leclerc V, et al,. Acute local tolerability of acidic aqueous vehicles delivered via Respimat (R) soft Mist(TM) inhaler in hyperreactive asthma patients. Respiration 2007; 74: 691-696.
133. Patel KR, et al,. Inhaled ethanolic and aqueous solutions via respimat soft mist inhaler are well-tolerated in asthma patients. Respiration 2006; 73: 434-440.
134. Bouyssou T, et al,. Pharmacological characterization of olodaterol, a novel inhaled beta(2)-Adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical models. J Pharmacol Exp Ther 2010; 334: 53-62.
135. Hindle M, Longest PW,. Condensational growth of combination drug-excipient submicrometer particles for targeted high-efficiency pulmonary delivery: evaluation of formulation and delivery device. J Pharm Pharmacol 2012; 64: 1254-1263.
136. Newman SP, et al,. An in vitro study to assess facial and ocular deposition from Respimat (R) Soft Mist (TM) inhaler. J Aeros Med-Deposit Clear Effects Lung 2007; 20: 7-12.
137. Schuster J, et al,. The AER(X)(TM) aerosol delivery system. Pharm Res 1997; 14: 354-357.
138. Davison S, et al,. Pharmacokinetics and acute safety of inhaled testosterone in postmenopausal women. J Clin Pharmacol 2005; 45: 177-184.
139. Farr SJ, Otulana BA,. Pulmonary delivery of opioids as pain therapeutics. Adv Drug Deliv Rev 2006; 58: 1076-1088.
140. Gonda I, et al,. Inhalation delivery systems with compliance and disease management capabilities. J Controlled Release 1998; 53: 269-274.
141. Otulana B, et al,. Safety and pharmacokinetics of inhaled morphine delivered using the AERx System in patients with moderate-to-severe asthma. Int J Clin Pharmacol Ther 2004; 42: 456-462.
142. Thipphawong JB, et al,. Analgesic efficacy of inhaled morphine in patients after bunionectomy surgery. Anesthesiology 2003; 99: 693-700.
143. Dershwitz M, et al,. Pharmacokinetics and pharmacodynamics of inhaled versus intravenous morphine in healthy volunteers. Anesthesiology 2000; 93: 619-628.
144. Ward ME, et al,. Morphine pharmacokinetics after pulmonary administration from a novel aerosol delivery system. Clin Pharmacol Ther 1997; 62: 596-609.
145. Mather LE, et al,. Pharmacokinetics of orally inhaled fentanyl in healthy subjects. J Clin Pharmacol 2000; 40: 1060.
146. Okumu FW, et al,. Evaluation of the AERx pulmonary delivery system for systemic delivery of a poorly soluble selective D-1 agonist, ABT-431. Pharm Res 2002; 19: 1009-1012.
147. Chan HK, et al,. Deposition of aqueous aerosol of technetium-99 m diethylene triamine penta-acetic acid generated and delivered by a novel system (AER(x)) in healthy subjects. Eur J Nucl Med 1999; 26: 320-327.
148. Cipolla DC, et al,. Bolus Administration of Ixml: Studying the Feasibility of Delivering High Doses of Drugs Using the AERx Pulmonary Delivery System. In: Respiratory Dru Delivery VII. Tarpon Springs, FL, USA: Serentec Press, Raleigh, NC, USA, 2000.
149. Sangwan S, et al,. Aerosolized protein delivery in asthma: gamma camera analysis of regional deposition and perfusion. J Aeros Med-Deposit Clear Effects Lung 2001; 14: 185-195.
150. Farr SJ, et al,. Comparison of in vitro and in vivo efficiencies of a novel unit-dose liquid aerosol generator and a pressurized metered dose inhaler. Int J Pharm 2000; 198: 63-70.
151. Geller D, et al,. Bolus inhalation of rhDNase with the AERx system in subjects with cystic fibrosis. J Aeros Med-Deposit Clear Effects Lung 2003; 16: 175-182.
152. Deshpande D, et al,. Aerosolization of lipoplexes using AERx (R) Pulmonary Delivery System. Aaps Pharmsci 2002; 4: 12-21.
153. Rosell J, et al,. Suppression of electrostatic changing of AERx aerosols. J Aeros Med 2001; 14: 405, P2-23.
154. Heinemann L,. New ways of insulin delivery. Int J Clin Pract 2011; 65: 31-46.
155. Boyd B, et al,. Effect of gender and device mouthpiece shape on bolus insulin aerosol delivery using the AER(x) pulmonary delivery system. Pharm Res 2004; 21: 1776-1782.
156. Mastrandrea LD, Quattrin T,. Clinical evaluation of inhaled insulin. Adv Drug Deliv Rev 2006; 58: 1061-1075.
157. Moses RG, et al,. Safety and efficacy of inhaled insulin (AERx((R)) iDMS(1)) compared with subcutaneous insulin therapy in patients with Type 1 diabetes: 1-year data from a randomized, parallel group trial. Diabet Med 2009; 26: 260-267.
158. Wilbanks TM, Schuster JA,. Aerosol drug delivery to the lung periphery using nano-scale technologies, In: 2005 International Conference on MEMS, NANO and Smart Systems, Proceedings. 2005: 127-128.
159. Chattopadhyay P, et al,. Production of solid lipid nanoparticle suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system. Adv Drug Deliv Rev 2007; 59: 444-453.
160. ® System. J Aeros Med 2001; 18: 101-102.
161. Deshpande DS, et al,. Gamma scintigraphic evaluation of a miniaturized AERx (R) pulmonary delivery system for aerosol delivery to anesthetized animals using a positive pressure ventilation system. J Aeros Med-Deposit Clear Effects Lung 2005; 18: 34-44.
162. de Boer AH, et al,. In vitro performance testing of the novel medspray (R) wet aerosol inhaler based on the principle of Rayleigh break-up. Pharm Res 2008; 25: 1186-1192.
163. Rayleigh L,. On the Instability of Jets. Proceed London Mathemat Soc 1878; 10: 4-13.
164. Weber C,. Zum Zerfall eines Flussigkeitsstrahles. J Appl Mathemat Mechanics/Zeitschrift fur Angewandte Mathematik und Mechanik 1931; 11: 136-154.
165. Munnik P, et al,. In vivo performance testing of the novel medspray (R) wet aerosol inhaler. J Aerosol Med Pulm Drug Deliv 2009; 22: 317-321.
166. Tang K, Gomez A,. Generation by electrospray of monodisperse water droplets for targeted drug-delivery by inhalation. J Aerosol Sci 1994; 25: 1237-1249.
167. Zimlich WC, et al,. The Development of a Novel Electrohydrodynamic Pulmonary Drug Delivery Device. in Respiratory Dru Delivery VII. 2000. Tarpon Springs, FL, USA; Raleigh, NC, USA: Serentec Press.
168. Clear N, et al,., Miller P, Shepherd M,. Electrohydrodynamic aerosol drug delivery: experience in early clinical development. J Aeros Med 2004; 17: 95, 9.
169. Smyth WF, Rodriguez V,. Recent studies of the electrospray ionisation behaviour of selected drugs and their application in capillary electrophoresis-mass spectrometry and liquid chromatography-mass spectrometry. J Chromatogr A 2007; 1159: 159-174.
170. Yurteri CU, et al,. Producing pharmaceutical particles via electrospraying with an emphasis on nano and nano structured particles-a review. Kona Powder Particle J 2010; 28: 91-115.
171. Kumbar SG, et al,. A preliminary report on a novel electrospray technique for nanoparticle based biomedical implants coating: precision electrospraying. J Biomed Mat Res Part B-Appl Biomat 2007; 81B: 91-103.
172. Xie J, et al,. Electrohydrodynamic atomization for biodegradable polymeric particle production. J Colloid Interface Sci 2006; 302: 103-112.
173. Ding L, et al,. Fabrication of monodispersed taxol-loaded particles using electrohydrodynamic atomization. J Controlled Release 2005; 102: 395-413.
174. Jung JH,. Electrohydrodynamic nano-spraying of ethanolic natural plant extracts. J Aerosol Sci 2011; 42: 725-736.
175. Jaworek A,. Electrostatic micro- and nanoencapsulation and electroemulsification: a brief review. J Microencapsul 2008; 25: 443-468.
176. Ijsebaert JC, et al,. Electro-hydrodynamic atomization of drug solutions for inhalation purposes. J Appl Physiol 2001; 91: 2735-2741.
177. Singh S, et al,. Parameterization of an electro-hydrodynamic atomization based aerosol generator. Part Sci Technol 2013; 31: 494-500.
178. Esposito-Festen JE, et al,. Pharmacokinetics of inhaled monodisperse beclomethasone as a function of particle size. Br J Clin Pharmacol 2007; 64: 328-334.
179. Davies DN, et al,. Liquid formations for electrohydrodymanic spraying containing polymer and suspended particles, USPTO, Editor. 2011, Battelle Memorial Institute, Columbus, OH, USA. p. 25.
180. Chattopadhyay S, et al,. Size distribution and morphology of liposome aerosols generated by two methodologies. Aerosol Sci Technol 2010; 44: 972-982.
181. Jayasinghe SN, Edirisinghe MJ,. Jet break-up in nano-suspensions during electrohydrodynamic atomization in the stable cone-jet mode. J Nanosci Nanotechnol 2005; 5: 923-926.
182. Charvat A, et al,. Time-resolved micro liquid desorption mass spectrometry: mechanism, features, and kinetic applications. Aust J Chem 2006; 59: 81-103.
183. Murariu M, et al,. Model peptide-based system used for the investigation of metal ions binding to histidine-containing polypeptides. Biopolymers 2010; 93: 497-508.
184. Pareta R, et al,. Electrohydrodynamic atomization of protein (bovine serum albumin). J Mat Sci-Mat Med 2005; 16: 919-925.
185. Lentz YK, et al,. Rationale for the selection of an aerosol delivery system for gene delivery. J Aeros Med-Deposit Clearan Effects Lung 2006; 19: 372-384.
186. Morozov VN, et al,. Generation and delivery of nanoaerosols from biological and biologically active substances. J Aerosol Sci 2014; 69: 48-61.
187. Yeo LY, Friend JR,. Ultrafast microfluidics using surface acoustic waves. Biomicrofluidics 2009; 3: 012002.
188. Alvarez M, et al,. Surface vibration induced spatial ordering of periodic polymer patterns on a substrate. Langmuir 2008; 24: 10629-10632.
189. Friend J, Yeo LY,. Microscale acoustofluidics: microfluidics driven via acoustics and ultrasonics. Rev Mod Phys 2011; 83: 647-704.
190. Qi AS, et al,. Miniature inhalation therapy platform using surface acoustic wave microfluidic atomization. Lab Chip 2009; 9: 2184-2193.
191. Qi A, et al,. Interfacial destabilization and atomization driven by surface acoustic waves. Phys Fluids 2008; 20: 074103.
192. Alvarez M, et al,. Rapid generation of protein aerosols and nanoparticles via surface acoustic wave atomization. Nanotechnology 2008; 19: 455103.
193. Alvarez M, et al,. Rapid production of protein-loaded biodegradable microparticles using surface acoustic waves. Biomicrofluidics 2009; 3: 014102.
194. Qi A, et al,. The extraction of liquid, protein molecules and yeast cells from paper through surface acoustic wave atomization. Lab Chip 2009; 10: 470-476.
195. Rajapaksa A, et al,. Effective pulmonary delivery of an aerosolized plasmid DNA vaccine via surface acoustic wave nebulization. Respir Res 2014; 15: 60.
196. Rajapaksa A, et al,. Enabling practical surface acoustic wave nebulizer drug delivery via amplitude modulation. Lab Chip 2014; 14: 1858-1865.
197. Li H, et al,. Surface acoustic wave concentration of particle and bioparticle suspensions. Biomed Microdevices 2007; 9: 647-656.
198. Tan MK, et al,. Microparticle collection and concentration via a miniature surface acoustic wave device. Lab Chip 2007; 7: 618-625.
199. Friend JR, et al,. Evaporative self-assembly assisted synthesis of polymeric nanoparticles by surface acoustic wave atomization. Nanotechnology 2008; 19: 145301.
200. Forde GM, et al,. Straightforward biodegradable nanoparticle generation through megahertz-order ultrasonic atomization. Appl Phys Lett 2006; 89: 4105.
201. Hindle M, et al,. High efficiency fine particle generation using novel condensation technology. In: Respiratory Drug Delivery VI. Hilton Head, SC, USA; Buffalo Grove, IL, USA: Interpharm Press, 1998.
202. Howell TM, Sweeney WR,. Aerosol and a Method and Apparatus for Generating Aerosol, USPTO, Editor. 1998, Philip Morris Incorporated. New York, NY, USA. p. 14.
203. Hong JN, et al,. Control of particle size by coagulation of novel condensation aerosols in reservoir chambers. J Aeros Med-Deposit Clear Effects Lung 2002; 15: 359-368.
204. Gupta R, et al,. Vehicle effects on the performance of a novel pharmaceutical condensation aerosol generator. AAPS PharmSci. 2001; 3: 3150 (suppl).
205. Gupta R, et al,. Solute and concentration effects in a novel pharmaceutical condensation aerosol generator. AAPS PharmSci 2001; 3: 3148 (suppl).
206. Shen X, et al,. Effect of energy on propylene glycol aerosols using the capillary aerosol generator. Int J Pharm 2004; 275: 249-258.
207. Li XH, et al,. Stability and characterization of perphenazine aerosols generated using the capillary aerosol generator. Int J Pharm 2005; 303: 113-124.
208. Werley MS, et al,. Non-clinical safety and pharmacokinetic evaluations of propylene glycol aerosol in Sprague-Dawley rats and Beagle dogs. Toxicology 2011; 287: 76-90.
209. CEN, Respiratory therapy equipment-Part 1: Nebulizing systems and their components, E.C.f. Standardization, Editor. 2007, BSI.
210. Sangwan S, et al,. Lung deposition and respirable mass during wet nebulization. J Aeros Med-Deposit Clear Effects Lung 2003; 16: 379-386.
211. Marple VA, et al,. Next generation pharmaceutical impactor (A new impactor for pharmaceutical inhaler testing). Part I: Design. J Aeros Med-Deposit Clear Effects Lung 2003; 16: 283-299.
212. Mitchell JP, Nagel MW,. Cascade impactors for the size characterization of aerosols from medical inhalers: their uses and limitations. J Aeros Med-Deposit Clear Effects Lung 2003; 16: 341 -+.
213. Mitchell J, et al,. In vitro and in vivo aspects of cascade impactor tests and inhaler performance: a review. Aaps Pharmscitech 2007; 8: 237-248.
214. Waldrep JC, et al,. Comparative analysis of methods to measure aerosols generated by a vibrating mesh nebulizer. J Aeros Med-Deposit Clear Effects Lung 2007; 20: 310-319.
215. Mitchell J, et al,. Non-impactor-based methods for sizing of aerosols emitted from orally inhaled and nasal drug products (OINDPs). AAPS PharmSciTech 2011; 12: 965-988.
216. Mitchell JP, Nagel MW,. Particle size analysis of aerosols from medicinal inhalers. KONA Powder Particle 2004; 22: 32-65.
217. de Boer AH, et al,. Characterization of inhalation aerosols: a critical evaluation of cascade impactor analysis and laser diffraction technique. Int J Pharm 2002; 249: 219-231.
218. Mitchell JP, et al,. Laser diffractometry as a technique for the rapid assessment of aerosol particle size from inhalers. J Aeros Med-Deposit Clear Effects Lung 2006; 19: 409-433.
219. Marple VA, et al,. Next generation pharmaceutical impactor: A new impactor for pharmaceutical inhaler testing. Part III. Extension of archival calibration to 15 L/min. J Aeros Med-Deposit Clear Effects Lung 2004; 17: 335-343.
220. Berg E, et al,. Determination of nebulizer droplet size distribution: a method based on impactor refrigeration. J Aeros Med-Deposit Clear Effects Lung 2007; 20: 97-104.
221. Berlinski A, Hayden JB,. Optimization of a procedure used to measure aerosol characteristics of nebulized solutions using a cooled next generation impactor. J Aerosol Med Pulm Drug Deliv 2010; 23: 397-404.
222. Bummer PM,. Interfacial Phenomena. In:, Hendrickson R, ed. Remington: The Science and Practice of Pharmacy. Baltimore, MD: Lippincott Williams & Wilkins, 2005: 280-292.
223. Minko T,. Interfacial Phenomena. In:, Sinko PJ, ed. Martin's Physical Pharmacy and Pharmaceutical Sciences. Baltimore, MD: Lippincott Williams & Wilkins, 2006: 437-467.
224. Carvalho TC, et al,. Application of a Pull on a Disk Method to Measure Surface Tension of Liquids. AAPS Pharm Sci Tech 2012; 13: 305-312.
225. Longer M,. Rheology. In:, Sinko PJ, ed. Martin's Physical Pharmacy and Pharmaceutical Sciences. Baltimore, MD: Lippincott Williams & Wilkins, 2006: 561-583.
226. Schnaare RL, et al,. Rheology. In:, Hendrickson R, ed. Remington: The Science and Practice of Pharmacy. Baltimore, MD: Lippincott Williams & Wilkins, 2005: 338-357.
227. Nagvekar AA, et al,. Current analytical methods used in the in vitro evaluation of nano-drug delivery systems. Curr Pharm Anal 2009; 5: 358-366.
228. Shekunov BY, et al,. Particle size analysis in pharmaceutics: principles, methods and applications. Pharm Res 2007; 24: 203-227.
229. Lyklema J,. Molecular interpretation of electrokinetic potentials. Curr Opin Colloid Interface Sci 2010; 15: 125-130.
230. Kallay N, et al,. Electrostatic potentials at solid/liquid interfaces. Croat Chem Acta 2010; 83: 357-370.
231. Barnes HA, et al.,. Rheology of Suspensions. In, Walters K, ed. An Introduction to Rheology. Amsterdam, The Netherlands: Elsevier, 1989: 115-137.
232. Derkach SR,. Rheology of emulsions. Adv Colloid Interface Sci 2009; 151: 1-23.